Search

Your search keyword '"Kahlert, Johnny"' showing total 394 results
Start Over Author "Kahlert, Johnny" Publication Year Range Last 50 years
394 results on '"Kahlert, Johnny"'

7. Time trends in the clinical management of cervical intraepithelial neoplasia grade 2: A Danish register‐based study.

Author

Eriksen, Dina Overgaard, Randrup, Tina Hovgaard, Lycke, Kathrine Dyhr, Damgaard, Rikke Kamp, Kahlert, Johnny, Ostenfeld, Eva Bjerre, Jensen, Pernille Tine, Wentzensen, Nicolas, Clarke, Megan A., and Hammer, Anne

Subjects
CERVICAL intraepithelial neoplasia, WATCHFUL waiting, CLINICAL indications, CHILDBEARING age, HUMAN papillomavirus vaccines, GENITAL warts
Abstract

Introduction: Active surveillance for cervical intraepithelial neoplasia grade 2 (CIN2) has been implemented recently in many countries, including the Nordic countries. In Denmark, the only eligibility criterion for active surveillance for CIN2 is that the woman should be of reproductive age. With this study, we aimed to evaluate clinical and socioeconomic characteristics in women with CIN2 managed by active surveillance or large loop excision of the transformation zone (LLETZ) and to evaluate temporal changes in the clinical management of CIN2. Material and Methods: We conducted a Danish nationwide study using data from healthcare registries. All female residents aged 18–40 years, diagnosed with incident CIN2 from January 1, 1998, to February 29, 2020, were included. We collected data on age, index cytology result, year of CIN2 diagnosis, region of residence, civil status, HPV vaccination status, and socioeconomic position indicators. The variables were tabulated overall and by management group (active surveillance vs. LLETZ). To evaluate time trends, we used joinpoint regression to calculate the annual percentage change (APC), including 95% confidence intervals (CI). Results: Of the 27 536 women with CIN2 included, 12 500 (45.4%) underwent active surveillance, and 15 036 (54.6%) underwent a LLETZ. Women undergoing active surveillance were younger, more often HPV‐vaccinated, and more likely to have a normal/low‐grade index cytology result than women undergoing LLETZ. Socioeconomic position indicators did not differ. Over time, the proportion of women undergoing active surveillance increased from 21.7% in 2004 to 73.6% in 2019 (APC 9.7, 95% CI 8.1–11.4). The proportion of women undergoing active surveillance aged <30 declined over time (APC −2.2, 95% CI −2.9 to −1.5). The proportion of women with normal/low‐grade index cytology increased slightly to 51.6% in 2019 (APC 0.8, 95% CI 0.4–1.3). Conclusions: The use of active surveillance for CIN2 has increased over the past two decades in Denmark. Observed differences in characteristics between women undergoing active surveillance vs LLETZ are likely related to indications for clinical management. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Long‐term outcomes after coronary intervention with biodegradable polymer stents in patients with acute coronary syndromes

Author

Noori, Manijeh, primary, Christiansen, Evald Høj, additional, Raungaard, Bent, additional, Junker, Anders, additional, Christensen, Martin Kirk, additional, Kahlert, Johnny, additional, Maeng, Michael, additional, Freeman, Phillip, additional, Hansen, Kirstine Nørregaard, additional, Terkelsen, Christian Juhl, additional, Ellert‐Gregersen, Julia, additional, Kristensen, Steen Dalby, additional, Veien, Karsten Tange, additional, Jakobsen, Lars, additional, and Jensen, Lisette Okkels, additional

Published
2023
Full Text
View/download PDF

15. Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention: A Randomized Noninferiority Trial With 1-Year Follow-Up (SORT OUT VIII Trial)

Author

Maeng, Michael, Bøtker, Hans Erik, Christiansen, Evald Høj, Raungaard, Bent, Jensen, Svend Eggert, Hansen, Henrik Steen, Jensen, Lisette Okkels, Bargsteen, Helle, Pedersen, Helle, Jørgensen, Lars P., Ottosen, Pia, Pedersen, Karin M., Thygesen, Kristian, Sørensen, Jacob Thorsted, Andersen, Henning Rud, Kahlert, Johnny, Terkelsen, Christian Juhl, Kristensen, Steen Dalby, Carstensen, Steen, Aarøe, Jens, Villadsen, Anton Boel, Lassen, Jens Flensted, Thim, Troels, Eftekhari, Ashkan, Veien, Karsten Tange, Hansen, Knud Nørregaard, and Junker, Anders

Published
2019
Full Text
View/download PDF

17. Long‐term outcomes after coronary intervention with biodegradable polymer stents in patients with acute coronary syndromes.

Author

Noori, Manijeh, Christiansen, Evald Høj, Raungaard, Bent, Junker, Anders, Christensen, Martin Kirk, Kahlert, Johnny, Maeng, Michael, Freeman, Phillip, Hansen, Kirstine Nørregaard, Terkelsen, Christian Juhl, Ellert‐Gregersen, Julia, Kristensen, Steen Dalby, Veien, Karsten Tange, Jakobsen, Lars, and Jensen, Lisette Okkels

Published
2024
Full Text
View/download PDF

20. Untreated cervical intraepithelial neoplasia grade 2 and subsequent risk of cervical cancer: population based cohort study.

Author

Dyhr Lycke, Kathrine, Kahlert, Johnny, Petersen, Lone Kjeld, Kamp Damgaard, Rikke, Li C. Cheung, Gravitt, Patti E., and Hammer, Anne

Subjects
TREATMENT of cervical intraepithelial neoplasia, PUBLIC health surveillance, CONFIDENCE intervals, AGE distribution, TIME, CERVICAL intraepithelial neoplasia, HEALTH outcome assessment, POPULATION geography, SEVERITY of illness index, RISK assessment, DESCRIPTIVE statistics, CERVIX uteri tumors, CYTOLOGY, RESIDENTIAL patterns, ODDS ratio, LONGITUDINAL method, DISEASE risk factors, DISEASE complications
Published
2023
Full Text
View/download PDF

21. Clinical outcomes three-year after revascularization with biodegradable polymer stents: ultrathin-strut sirolimus-eluting stent versus biolimus-eluting stent: from the Scandinavian organization for randomized trials with clinical outcome VII trial

Author

Ellert, Julia, Maeng, Michael, Raungaard, Bent, Hansen, Knud Nørregaard, Kahlert, Johnny, Jensen, Svend Eggert, Bøtker, Hans Erik, Hansen, Henrik Steen, Lassen, Jens Flensted, Christiansen, Evald Høj, and Jensen, Lisette Okkels

Published
2020
Full Text
View/download PDF

22. Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention: The SORT OUT IX Trial

Author

Jensen, Lisette Okkels, Maeng, Michael, Raungaard, Bent, Kahlert, Johnny, Ellert, Julia, Jakobsen, Lars, Villadsen, Anton Boel, Veien, Karsten Tange, Kristensen, Steen Dalby, Ahlehoff, Ole, Carstensen, Steen, Christensen, Martin Kirk, Terkelsen, Christian Juhl, Engstroem, Thomas, Hansen, Knud Nørregaard, Bøtker, Hans Erik, Aaroe, Jens, Thim, Troels, Thuesen, Leif, Freeman, Philip, Aziz, Ahmed, Eftekhari, Ashkan, Junker, Anders, Jensen, Svend Eggert, Lassen, Jens Flensted, Hansen, Henrik Steen, and Christiansen, Evald Høj

Published
2020
Full Text
View/download PDF

23. Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial

Author

Hansen, Kirstine Nørregaard, primary, Jensen, Lisette Okkels, additional, Maeng, Michael, additional, Christensen, Martin Kirk, additional, Noori, Manijeh, additional, Kahlert, Johnny, additional, Jakobsen, Lars, additional, Junker, Anders, additional, Freeman, Phillip, additional, Ellert-Gregersen, Julia, additional, Raungaard, Bent, additional, Terkelsen, Christian Juhl, additional, Veien, Karsten Tange, additional, and Christiansen, Evald Høj, additional

Published
2023
Full Text
View/download PDF

24. Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual‐therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent

Author

Jakobsen, Lars, primary, Christiansen, Evald H., additional, Freeman, Phillip, additional, Kahlert, Johnny, additional, Veien, Karsten, additional, Maeng, Michael, additional, Raungaard, Bent, additional, Ellert, Julia, additional, Kristensen, Steen D., additional, Christensen, Martin K., additional, Terkelsen, Christian J., additional, Thim, Troels, additional, Eftekhari, Ashkan, additional, Jensen, Rebekka V., additional, Støttrup, Nicolaj B., additional, Junker, Anders, additional, Hansen, Henrik S., additional, and Jensen, Lisette O., additional

Published
2022
Full Text
View/download PDF

26. Performance of HPV E4 and p16INK4a biomarkers in predicting regression of cervical intraepithelial neoplasia grade 2 (CIN2): protocol for a historical cohort study

Author

Damgaard, Rikke Kamp, primary, Jenkins, David, additional, de Koning, Maurits NC, additional, Quint, Wim GV, additional, Stoler, Mark H, additional, Doorbar, John, additional, Kahlert, Johnny, additional, Gravitt, Patti E, additional, Steiniche, Torben, additional, Petersen, Lone Kjeld, additional, and Hammer, Anne, additional

Published
2022
Full Text
View/download PDF

27. Impact of diabetes on 1-year clinical outcome in patients undergoing revascularization with the BioFreedom stents or the Orsiro stents from the SORT OUT IX trial

Author

Hansen, Kirstine Nørregaard, Maeng, Michael, Raungaard, Bent, Engstrøm, Thomas, Veien, Karsten Tange, Kristensen, Steen Dalby, Ellert-Gregersen, Julia, Jensen, Svend Eggert, Junker, Anders, Kahlert, Johnny, Jakobsen, Lars, Christiansen, Evald Høj, Jensen, Lisette Okkels, Hansen, Kirstine Nørregaard, Maeng, Michael, Raungaard, Bent, Engstrøm, Thomas, Veien, Karsten Tange, Kristensen, Steen Dalby, Ellert-Gregersen, Julia, Jensen, Svend Eggert, Junker, Anders, Kahlert, Johnny, Jakobsen, Lars, Christiansen, Evald Høj, and Jensen, Lisette Okkels

Abstract

This sub-study of the SORT OUT IX trial sought to compare clinical outcomes between patients with diabetes randomized to implantation of either the polymer-free biolimus A9-coated BioFreedom stent (BF-BES) or the ultra-thin strut, biodegradable polymer sirolimus-eluting Orsiro stent (O-SES). Patients with diabetes have an increased risk of target lesion failure (TLF) after percutaneous coronary intervention (PCI). The impact of different stent types in patients with diabetes is still discussed. A total of 607 of the 3151 patients (19.3%) enrolled in the SORT OUT IX study had diabetes. Randomization was stratified by patients with/without diabetes; 304 received BF-BES and 303 O-SES. The primary endpoint was TLF, which was a composite of cardiac death, myocardial infarction (not related to other than the index lesion) and target lesion revascularization (TLR) within 1 year. After 1 year, patients with diabetes had higher TLF (7.2% vs. 3.7%, incidence rate ratio [IRR]: 1.65; 95% confidence interval [CI]: 1.08–2.50), than patients without diabetes. TLF did not differ significantly between BF-BES and O-SES in patients with diabetes (8.2% vs. 6.3%, IRR: 1.17; 95% CI: 0.63–2.20). In patients with diabetes, cardiac death occurred in 2.3% of BF-BES and in 3.6% of O-SES (IRR: 0.58; 95% CI: 0.23–1.45) and TLR occurred in 5.3% and 2.3% of BF-BES and O-SES, respectively (IRR: 2.12; 95% CI: 0.81–5.56). Definite stent thrombosis rates of 1.3% were found in both stent types. Patients with diabetes had higher 1-year TLF rate after PCI compared to patients without diabetes, whereas TLF did not differ significantly between the two stent types BF-BES and O-SES in patients with diabetes.

Published
2022

28. Polymer-free biolimus-coated stents versus ultrathin-strut biodegradable polymer sirolimus-eluting stents:two-year outcomes of the randomised SORT OUT IX trial

Author

Ellert-Gregersen, Julia, Jensen, Lisette Okkels, Jakobsen, Lars, Freeman, Phillip Michael, Eftekhari, Ashkan, Maeng, Michael, Raungaard, Bent, Engstroem, Thomas, Kahlert, Johnny, Hansen, Henrik Steen, Christiansen, Evald Høj, Ellert-Gregersen, Julia, Jensen, Lisette Okkels, Jakobsen, Lars, Freeman, Phillip Michael, Eftekhari, Ashkan, Maeng, Michael, Raungaard, Bent, Engstroem, Thomas, Kahlert, Johnny, Hansen, Henrik Steen, and Christiansen, Evald Høj

Abstract

Background: For patients with high bleeding risk, the BioFreedom stent is safer and more effective than a bare metal stent. However, at the one-year follow-up of the SORT OUT IX trial, the BioFreedom stent did not meet the criteria for non-inferiority for target lesion failure (TLF) when compared with the Orsiro stent and had a higher incidence of target lesion revascularisation (TLR). Aims: The aim of the study was to compare the two-year outcomes following coronary implantation of the BioFreedom or the Orsiro stents in all-comer patients. Methods: The Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) IX trial is a prospective, multicentre, randomised clinical trial comparing the BioFreedom and the Orsiro stents. The primary endpoint, TLF, was a composite of cardiac death, myocardial infarction (MI; not related to other lesions) and TLR. Results: A total of 1,572 patients were randomised to treatment with the BioFreedom stent and 1,579 patients with the Orsiro stent. At two-year follow-up, TLF was 7.8% in the BioFreedom and 6.3% in the Orsiro stent groups (rate ratio [RR] 1.23, 95% confidence interval [CI]: 0.94-1.61). Risks of cardiac death, MI and definite stent thrombosis did not differ significantly between the groups, whereas more patients in the BioFreedom group had TLR (5.1% vs 2.6%; RR 1.98, 95% CI: 1.26-2.89) attributable to a higher risk of TLR within the first year (3.5% vs 1.3%; RR 2.77, 95% CI: 1.66-4.62). Conclusions: At two years, there were no significant differences between the BioFreedom and Orsiro stents for TLF. TLR was significantly higher with the BioFreedom stent due to higher risk of TLR within the first year.

Published
2022

29. Polymer-free biolimus-coated stents versus ultrathin-strut biodegradable polymer sirolimus-eluting stents: two-year outcomes of the randomised SORT OUT IX trial

Author

Ellert-Gregersen, Julia, primary, Jensen, Lisette Jensen, additional, Jakobsen, Lars, additional, Freeman, Phillip Michael, additional, Eftekhari, Ashkan, additional, Maeng, Michael, additional, Raungaard, Bent, additional, Engstroem, Thomas, additional, Kahlert, Johnny, additional, Hansen, Henrik Hansen, additional, and Christiansen, Evald Høj, additional

Published
2022
Full Text
View/download PDF

30. Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent

Author

Jakobsen, Lars, primary, Christiansen, Evald H., additional, Freeman, Phillip, additional, Kahlert, Johnny, additional, Veien, Karsten, additional, Maeng, Michael, additional, Raungaard, Bent, additional, Ellert, Julia, additional, Kristensen, Steen D., additional, Christensen, Martin K., additional, Terkelsen, Christian J., additional, Thim, Troels, additional, Eftekhari, Ashkan, additional, Jensen, Rebekka V., additional, Støttrup, Nicolaj B., additional, Junker, Anders, additional, Hansen, Henrik S., additional, and Jensen, Lisette O., additional

Published
2022
Full Text
View/download PDF

32. Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual‐therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent.

Author

Jakobsen, Lars, Christiansen, Evald H., Freeman, Phillip, Kahlert, Johnny, Veien, Karsten, Maeng, Michael, Raungaard, Bent, Ellert, Julia, Kristensen, Steen D., Christensen, Martin K., Terkelsen, Christian J., Thim, Troels, Eftekhari, Ashkan, Jensen, Rebekka V., Støttrup, Nicolaj B., Junker, Anders, Hansen, Henrik S., and Jensen, Lisette O.

Published
2023
Full Text
View/download PDF

33. Impact of diabetes on 1‐year clinical outcome in patients undergoing revascularization with the BioFreedom stents or the Orsiro stents from the SORT OUT IX trial

Author

Hansen, Kirstine Nørregaard, primary, Maeng, Michael, additional, Raungaard, Bent, additional, Engstrøm, Thomas, additional, Veien, Karsten Tange, additional, Kristensen, Steen Dalby, additional, Ellert‐Gregersen, Julia, additional, Jensen, Svend Eggert, additional, Junker, Anders, additional, Kahlert, Johnny, additional, Jakobsen, Lars, additional, Christiansen, Evald Høj, additional, and Jensen, Lisette Okkels, additional

Published
2022
Full Text
View/download PDF

34. Background Rates of 41 Adverse Events of Special Interest for COVID-19 Vaccines in 10 European Healthcare Databases - An ACCESS Cohort Study

Author

Willame, Corinne, primary, Dodd, Caitlin, additional, Carlos, Durán, additional, Roel, Elbers, additional, Gini, Rosa, additional, Bartolini, Claudia, additional, Paoletti, Olga, additional, Wang, Lei, additional, Ehrenstein, Vera, additional, Kahlert, Johnny, additional, Haug, Ulrike, additional, Schink, Tania, additional, Diez-Domingo, Javier, additional, Mira-Iglesias, Ainara, additional, Vergara-Hernández, Carlos, additional, Giaquinto, Carlo, additional, Barbieri, Elisa, additional, Stona, Luca, additional, Huerta, Consuelo, additional, Martín-Pérez, Mar, additional, García-Poza, Patricia, additional, de Burgos González, Airam, additional, Martínez-González, María, additional, Bryant, Verónica, additional, Villalobos, Felipe, additional, Pallejà-Millán, Meritxell, additional, Aragón, Maria, additional, Juan Jose, Carreras, additional, Souverein, Patrick, additional, Nicolas, Thurin, additional, Weibel, Daniel, additional, Olaf, Klungel, additional, and Miriam, Sturkenboom, additional

Published
2022
Full Text
View/download PDF

35. Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared With the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial

Author

Hansen, Kirstine, Jensen, Lisette Okkels, Maeng, Michael, Christensen, Martin Kirk, Kahlert, Johnny, Jakobsen, Lars, Junker, Anders, Freeman, Phillip, Noori, Manijeh, Ellert, Julia, Raungaard, Bent, Terkelsen, Christian, Hansen, Henrik, and Christiansen, Evald

Published
2021

37. TCT-151 Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared With the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial

Author

Hansen, Kirstine, primary, Jensen, Lisette Okkels, additional, Maeng, Michael, additional, Christensen, Martin Kirk, additional, Kahlert, Johnny, additional, Jakobsen, Lars, additional, Junker, Anders, additional, Freeman, Phillip, additional, Noori, Manijeh, additional, Ellert, Julia, additional, Raungaard, Bent, additional, Terkelsen, Christian, additional, Hansen, Henrik, additional, and Christiansen, Evald, additional

Published
2021
Full Text
View/download PDF

38. TCT-278 Five-Year Outcomes After Revascularization With the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Orsiro Stent or the Biodegradable Polymer Biolimus-Eluting Nobori Stent in Patients With and Without Acute Coronary Syndromes: From the SORT OUT VII Trial

Author

Noori, Manijeh, primary, Christiansen, Evald, additional, Raungaard, Bent, additional, Junker, Anders, additional, Christensen, Martin Kirk, additional, Kahlert, Johnny, additional, Jakobsen, Lars, additional, Freeman, Phillip, additional, Hansen, Kirstine, additional, Terkelsen, Christian, additional, Ellert, Julia, additional, Kristensen, Steen Dalby, additional, Veien, Karsten, additional, Maeng, Michael, additional, Hansen, Henrik, additional, and Jensen, Lisette Okkels, additional

Published
2021
Full Text
View/download PDF

42. Trends in Hysterectomy Incidence Rates During 2000–2015 in Denmark: Shifting from Abdominal to Minimally Invasive Surgical Procedures

Author

Lycke,Kathrine Dyhr, Kahlert,Johnny, Damgaard,Rikke, Mogensen,Ole, Hammer,Anne, Lycke,Kathrine Dyhr, Kahlert,Johnny, Damgaard,Rikke, Mogensen,Ole, and Hammer,Anne

Abstract

Kathrine Dyhr Lycke,1,2 Johnny Kahlert,3 Rikke Damgaard,1,2 Ole Mogensen,2,4 Anne Hammer1,2,4 1Department of Obstetrics and Gynecology, NIDO | Denmark, Gødstrup Hospital, Herning, Denmark; 2Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; 3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; 4Department of Obstetrics and Gynecology, Aarhus University Hospital, Aarhus, DenmarkCorrespondence: Kathrine Dyhr LyckeDepartment of Obstetrics and Gynecology, NIDO | Denmark, Gødstrup Hospital, Gl. Landevej 61, Herning, DK-7400, DenmarkEmail katlyc@clin.au.dkBackground: Hysterectomy (removal of the uterus) is a common surgical procedure in gynecology. Although minimally invasive surgical procedures have been introduced, hysterectomy is still associated with risk of short- and long-term complications. Given that hysterectomized women are no longer at risk of either hysterectomy or being diagnosed with endometrial or cervical cancer, it is important to describe trends in hysterectomy rates.Objective: To describe trends in hysterectomy incidence rates overall and stratified by age, indication, and procedure.Methods: Nationwide population-based cohort study using Danish national registries, 2000– 2015, was conducted. We calculated the overall hysterectomy-corrected and age-standardized incidence rates of hysterectomy among women ≥ 20 years old. Incidence rates were stratified by age group, indication, and surgical procedure. We performed trend analyses using Joinpoint regression, thereby estimating the average annual percentage change (AAPC).Results: A total of 98,484 women had a hysterectomy during the study period, corresponding to an overall age-standardized, hysterectomy-corrected hysterectomy incidence rate (SIR) of 351.1 per 100,000 person-years (95% CI 348.9;353.3). SIR of hysterectomy declined over time (AAPC − 1.4; 95% CI − 1.9;-1.0), which was driven by a decline i

Published
2021

43. Assessing the current feces identification method of the European otter Lutra lutra

Author

Andersen, Liselotte Wesley, Schousgaard, Henriette Sallo, Kahlert, Johnny, Linnet, Anton, Jensen, Ole Hyttel, Thomsen, Erik Arnfred, Sørensen, Flemming, Baagøe, Hans Jørgen, Frikke, John, Jacobsen, Henrik, Håkansson, Bo, Loeschcke, Volker, Madsen, Aksel Bo, Andersen, Liselotte Wesley, Schousgaard, Henriette Sallo, Kahlert, Johnny, Linnet, Anton, Jensen, Ole Hyttel, Thomsen, Erik Arnfred, Sørensen, Flemming, Baagøe, Hans Jørgen, Frikke, John, Jacobsen, Henrik, Håkansson, Bo, Loeschcke, Volker, and Madsen, Aksel Bo

Abstract

In the past the European otter Lutra lutra was distributed throughout most of Europe but since the 1980s its distributional range has been reduced. Currently, the otter population is increasing. Conservation efforts have been implemented, however due to the natural elusiveness of the species it is difficult to monitor. Non-invasive sampling has proven to be the most effective method to derive population parameters such as presence/absence, genetic variability and population structure in European otters. The method to collect non-invasive samples is robust and provides reliable data. This study investigates the validity of the present state-of-The-Art method of identifying otter feces, and suggests modifications and improvements of the method. Results from the comparison of field collected data and data derived from a blind test show that the method is applicable in areas abundant with otters, however the method loses its power in the periphery of the distributional range. In these areas, it would be relevant to supplement traditional sampling with DNA analysis to verify the identification of the sample.

Published
2021

44. Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project

Author

RWE/Causal inference, Epi Infectieziekten Team 2, Data Science & Biostatistiek, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Willame, Corinne, Dodd, Caitlin, van der Aa, Lieke, Picelli, Gino, Emborg, Hanne-Dorthe, Kahlert, Johnny, Gini, Rosa, Huerta, Consuelo, Martín-Merino, Elisa, McGee, Chris, de Lusignan, Simon, Roberto, Giuseppe, Villa, Marco, Weibel, Daniel, Titievsky, Lina, Sturkenboom, Miriam C J M, RWE/Causal inference, Epi Infectieziekten Team 2, Data Science & Biostatistiek, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Willame, Corinne, Dodd, Caitlin, van der Aa, Lieke, Picelli, Gino, Emborg, Hanne-Dorthe, Kahlert, Johnny, Gini, Rosa, Huerta, Consuelo, Martín-Merino, Elisa, McGee, Chris, de Lusignan, Simon, Roberto, Giuseppe, Villa, Marco, Weibel, Daniel, Titievsky, Lina, and Sturkenboom, Miriam C J M

Published
2021

47. Twenty-Year Temporal Trends in Risk of Ischemic Stroke in Incident Type 2 Diabetes: A Danish Population-Based Cohort Study.

Author

Gyldenkerne, Christine, Kahlert, Johnny, Olesen, Kevin K.W., Thrane, Pernille G., Sørensen, Henrik T., Thomsen, Reimar W., and Maeng, Michael

Abstract

OBJECTIVE: We examined temporal trends in risk of first-time ischemic stroke in patients with incident type 2 diabetes mellitus (T2DM) and no prior atherosclerotic cardiovascular disease (ASCVD). RESEARCH DESIGN AND METHODS: Using nationwide health registries, we identified all patients with incident T2DM without a prior hospital diagnosis of ASCVD from 1996 to 2015 in Denmark. Patients were assigned to 5-year periods based on the date of T2DM diagnosis and were followed for 5 years. Each patient was matched by sex and age with up to three individuals from the general population. Temporal trends in ischemic stroke were examined using Cox regression to compute hazard ratios (HRs). Temporal use of prophylactic cardiovascular medications was also assessed. RESULTS: The study comprised 288,825 patients with incident T2DM and 782,232 general population individuals. From 1996–2000 to 2011–2015, the 5-year risk of first-time ischemic stroke was approximately halved in the T2DM cohort (5.2% vs. 2.7%; sex- and age-adjusted HR 0.52 [95% CI 0.49–0.55]). Patients diagnosed in 2011–2015 had increased risk of ischemic stroke compared with individuals in the general population; however, the risk difference narrowed over time (5.2% vs. 2.9% in 1996–1999 [difference 2.3%]; 2.7% vs. 2.0% in 2011–2015 [difference 0.7%]). Use of prophylactic cardiovascular medications increased markedly during the overall study period, especially use of statins (from 5% to 50%) and multiple antihypertensive drugs (from 18% to 33%). CONCLUSIONS: From 1996 to 2015, the 5-year risk of first-time ischemic stroke was approximately halved in patients with incident T2DM and no prior ASCVD, coinciding with markedly increased use of prophylactic cardiovascular medications. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study

Author

Thomsen, Reimar W., primary, Knudsen, Jakob S., additional, Kahlert, Johnny, additional, Baggesen, Lisbeth M., additional, Lajer, Maria, additional, Holmgaard, Pia H., additional, Vedin, Ola, additional, Ustyugova, Anastasia, additional, and Sørensen, Henrik T., additional

Published
2021
Full Text
View/download PDF

50. Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial

Author

Jakobsen, Lars, primary, Christiansen, Evald H., additional, Freeman, Phillip, additional, Kahlert, Johnny, additional, Veien, Karsten, additional, Maeng, Michael, additional, Raungaard, Bent, additional, Ellert, Julia, additional, Villadsen, Anton B., additional, Kristensen, Steen D., additional, Ahlehoff, Ole, additional, Christensen, Martin K., additional, Terkelsen, Christian J., additional, Erik Bøtker, Hans, additional, Aaroe, Jens, additional, Thim, Troels, additional, Thuesen, Leif, additional, Aziz, Ahmed, additional, Eftekhari, Ashkan, additional, Jensen, Rebekka V., additional, Støttrup, Nicolaj B., additional, Rasmussen, Jeppe G., additional, Junker, Anders, additional, Jensen, Svend E., additional, Hansen, Henrik S., additional, and Jensen, Lisette O., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results